BlossomHill Therapeutics (BLSM) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BlossomHill Therapeutics is the larger company by market cap ($461.2 million vs $460.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | GYRE |
|---|---|---|
| Share price | $14.51 | $4.21 |
| Market cap | $461.20M | $460.79M |
| 1-day change | +0.69% | -6.86% |
| YTD return | — | -40.37% |
| 1-year return | — | -44.24% |
| 5-year return | — | -77.55% |
| Forward P/E | — | 70.17 |
| EPS (TTM) | $-10.38 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $116.59M |
| Revenue growth (YoY) | — | +10.24% |
| Net income (latest FY) | — | $9.88M |
| Gross margin | — | 95.35% |
| Operating margin | — | 9.85% |
| Net margin | — | 8.47% |
| 52-week high | $27.99 | $9.14 |
| 52-week low | $11.02 | $3.97 |
| Distance from 52-week high | -48.16% | -53.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +143.97% | +343.47% |
| Average volume | 193.15K | 181.04K |
| Shares outstanding | 31.78M | 109.45M |
| Employees | 69 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
BLSM vs GYRE FAQ
Which is bigger, BlossomHill Therapeutics or Gyre Therapeutics?
BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $461.20M compared with $460.79M for Gyre Therapeutics (GYRE).
Are BlossomHill Therapeutics and Gyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.